Milestone Pharmaceuticals Ownership
| MIST Stock | USD 2.02 0.02 1.00% |
Shares in Circulation | First Issued 2018-03-31 | Previous Quarter 66.2 M | Current Value 66.2 M | Avarage Shares Outstanding 36.1 M | Quarterly Volatility 13 M |
Milestone |
Milestone Stock Ownership Analysis
About 57.0% of the company shares are owned by institutional investors. The book value of Milestone Pharmaceuticals was now reported as 0.39. The company recorded a loss per share of 0.8. Milestone Pharmaceuticals had not issued any dividends in recent years. The entity had 1-1 split on the 24th of March 2020. Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company was incorporated in 2003 and is headquartered in Montral, Canada. Milestone Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 29 people. To find out more about Milestone Pharmaceuticals contact Joseph MBA at 514 336 0444 or learn more at https://www.milestonepharma.com.Besides selling stocks to institutional investors, Milestone Pharmaceuticals also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Milestone Pharmaceuticals' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Milestone Pharmaceuticals' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Milestone Pharmaceuticals Quarterly Liabilities And Stockholders Equity |
|
Milestone Pharmaceuticals Insider Trades History
Less than 1% of Milestone Pharmaceuticals are currently held by insiders. Unlike Milestone Pharmaceuticals' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Milestone Pharmaceuticals' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Milestone Pharmaceuticals' insider trades
Milestone Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Milestone Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Milestone Pharmaceuticals backward and forwards among themselves. Milestone Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Milestone Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Stonepine Capital Management Llc | 2024-09-30 | 999.8 K | Morgan Stanley - Brokerage Accounts | 2024-09-30 | 918.3 K | Ikarian Capital, Llc | 2024-09-30 | 466 K | Altium Capital Management, Lp | 2024-09-30 | 440 K | Boxer Capital Llc | 2024-09-30 | 309 K | Envestnet Asset Management Inc | 2024-09-30 | 70.6 K | Ancora Advisors Llc | 2024-09-30 | 60 K | Squarepoint Ops Llc | 2024-09-30 | 54.2 K | Atria Investments Llc | 2024-09-30 | 40.4 K | Blackrock Inc | 2024-09-30 | 5 M | Rtw Investments, Llc | 2024-09-30 | 3.3 M |
Milestone Pharmaceuticals Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Milestone Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Milestone Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Milestone Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Milestone Pharmaceuticals Outstanding Bonds
Milestone Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Milestone Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Milestone bonds can be classified according to their maturity, which is the date when Milestone Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View |
Milestone Pharmaceuticals Corporate Filings
F4 | 29th of January 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
10Q | 12th of November 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
13A | 29th of October 2024 An amended filing to the original Schedule 13G | ViewVerify |
F3 | 5th of September 2024 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Milestone Stock Analysis
When running Milestone Pharmaceuticals' price analysis, check to measure Milestone Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Milestone Pharmaceuticals is operating at the current time. Most of Milestone Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Milestone Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Milestone Pharmaceuticals' price. Additionally, you may evaluate how the addition of Milestone Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.